The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Open accessAbstract
Summary Respiratory syncytial virus (RSV) is the second most common cause of infant mortality and an important cause of morbidity and mortality in older adults. Efforts to develop an RSV vaccine or immunoprophylaxis remain highly active. Thirty-three RSV prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particle-based, live-attenuated, chimeric, and nucleic acid in addition to monoclonal antibodies (mAbs). Eight candidates are in phase III clinical trials. Understanding the epitopes targeted by highly neutralizing antibodies has resulted in a shift from empirical to rational and structure-based vaccine and mAb design. An extended half-life mAb for all infants is likely within one year of regulatory approval for high income countries. Live-attenuated vaccines are in development for older infants. Subunit vaccines are in late-stage trials for pregnant women to protect infants, while vector, subunit and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of an RSV vaccine globally. This review gives an overview of RSV vaccines and mAbs in clinical development highlighting different target populations, antigens, and latest trial results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,226
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationStructure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Self-citationNirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Hammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Grenham, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110275 · Cited by 1,027
Self-citationNair, H., Brooks, W. A., Katz, M., Roca, A., Berkley, J. A., Madhi, S. A., Simmerman, J. M., Gordon, A., Sato, M., Howie, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61051-9 · Cited by 1,006
Self-citationSingle-Dose Nirsevimab for Prevention of RSV in Preterm Infants
Griffin, M. P., Yuan, Y., Takas, T., Domachowske, J. B., Madhi, S. A., Manzoni, P., Simões, E. A. F., Esser, M. T., Khan, A. A., Dubovsky, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913556 · Cited by 762
Glezen, W. P., Paredes, A., Allison, J. E., Taber, L. H., & Frank, A. L. (1981) · The Journal of Pediatrics · doi:10.1016/s0022-3476(81)80829-3 · Cited by 689
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457
Self-citation
Cited by
Bender, R. G., Sirota, S. B., Swetschinski, L. R., Dominguez, R.-M. V., Novotney, A., Wool, E. E., Ikuta, K. S., Vongpradith, A., Rogowski, E. L. B., Doxey, M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00176-2 · Cited by 596
Yuan, J., Chen, J., Zhao, Q., Xu, J., Li, X., Zhang, Y., Li, H., Chen, X., Zhao, L., Zhang, X., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1558482 · Cited by 8
Metadata
- Authors
- Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., Feikin, D., Fitzpatrick, T., Fong, Y., Graham, B. S., Heikkinen, T., Higgins, D., Hirve, S., Klugman, K. P., Kragten-Tabatabaie, L., Lemey, P., Libster, R., Löwensteyn, Y., Mejias, A., Munoz, F. M., Munywoki, P. K., Mwananyanda, L., Nair, H., Nunes, M. C., Ramilo, O., Richmond, P., Ruckwardt, T. J., Sande, C., Srikantiah, P., Thacker, N., Waldstein, K. A., Weinberger, D., Wildenbeest, J., Wiseman, D., Zar, H. J., Zambon, M., & Bont, L.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 23
- Issue
- 1
- Pages
- e2-e21
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W4297452555
- Cited by
- 420
- References
- 70
- FWCI
- 56.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. https://app.cochat.ai/papers/10.1016/s1473-3099(22)00291-2
- The paper
- Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., Feikin, D., Fitzpatrick, T., Fong, Y., Graham, B. S., Heikkinen, T., Higgins, D., Hirve, S., Klugman, K. P., Kragten-Tabatabaie, L., . . . Bont, L. (2023). Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(22)00291-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
